HighQC™ Human IPSC From Fibroblast-Monocarboxylate Transporter 9-Specific Thyroid Hormone Cell Transporter Deficiency

Description

HighQC™ Human IPSC From Fibroblast-Monocarboxylate Transporter 9-Specific Thyroid Hormone Cell Transporter Deficiency is a disease-specific human induced pluripotent stem cell line derived from dermal fibroblasts of a donor with a diagnosed deficiency in the Monocarboxylate Transporter 9 (MCT9), encoded by the SLC16A9 gene. This cell line was generated using a non-integrating episomal plasmid method. The resulting iPSCs (induced pluripotent stem cells) exhibit adherent growth with a high nucleus-to-cytoplasm ratio. They maintain pluripotency for MCT9-related transport mechanism research. These MCT9 deficiency iPSCs retain the fundamental capacity for trilineage differentiation into cell types of the ectoderm, mesoderm, and endoderm germ layers. Core pluripotency marker SSEA-4 is expressed. The cells undergo rigorous screening and isolation procedures, and are rigorously tested to ensure they are free of contamination from HIV-1, HBV, HCV, Syphilis, Mycoplasma, Fungi, Yeast, and Bacteria.